Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
US-11951106-B2 · Apr 9, 2024 · US
US12409175B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12409175-B2 |
| Application number | US-202418441901-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 14, 2024 |
| Priority date | Jul 28, 2014 |
| Publication date | Sep 9, 2025 |
| Grant date | Sep 9, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
Opening claim text (preview).
The invention claimed is: 1. An aqueous suspension comprising reversible clusters of drug loaded ion-exchange resin particles, said clusters have a D50 value of at least 2 micrometers and the drug loaded ion-exchange resin particles have a particle size distribution characterized in that the D90 value is 70 to 900 nanometers, wherein the drug is brimonidine tartrate, and the brimonidine tartrate is present at a concentration of 0.35% w/v. 2. The aqueous suspension of claim 1 , wherein the ion-exchange resin is a cross-linked polystyrene with sulfonic acid groups. 3. The aqueous suspension of claim 1 , wherein the ion-exchange resin is sodium polystyrene divinyl benzene sulphonate. 4. The aqueous suspension of claim 3 , wherein the brimonidine tartrate is present at a concentration of 0.35% w/v and the sodium polystyrene divinyl benzene sulphonate is present at a concentration of 0.35% w/v. 5. The aqueous suspension of claim 1 , further comprising: (i) hydroxypropyl methylcellulose, (ii) polyvinylpyrrolidone, (iii) carbomer, and (iv) edetate disodium. 6. The aqueous suspension of claim 5 , further comprising: (v) benzalkonium chloride, (vi) N-laurylsarcosine sodium, (vii) mannitol, and (viii) tromethamine. 7. The aqueous suspension of claim 1 , comprising 0.35% w/v sodium polystyrene divinyl benzene sulphonate and further comprising: (i) 0.3% w/v hydroxypropyl methylcellulose, (ii) 1.2% w/v polyvinylpyrrolidone, (iii) 0.1% w/v carbomer, and (iv) 0.1% w/v edetate disodium. 8. The aqueous suspension of claim 7 , further comprising: (v) benzalkonium chloride, (vi) 0.06% w/v N-laurylsarcosine sodium, (vii) 4.5% w/v mannitol, and (viii) 0.32% w/v tromethamine. 9. The aqueous suspension of claim 1 , wherein the aqueous suspension has an osmolality of 250-375 mOsm/kg. 10. The aqueous suspension of claim 1 , wherein the aqueous suspension is suitable for once-a-day topical instillation. 11. A method of reducing elevated intraocular pressure in a patient in need thereof comprising topically administering once daily to an eye of the patient an aqueous suspension of claim 1 . 12. The method of claim 11 , wherein the patient suffers from glaucoma. 13. A method of reducing elevated intraocular pressure in a patient in need thereof comprising topically administering once daily to an eye of the patient an aqueous suspension of claim 6 . 14. The method of claim 13 , wherein the patient suffers from glaucoma.
obtained by reactions only involving unsaturated carbon-to-carbon bonds · CPC title
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title
Solutions {(composition of solutions A61K47/00)} · CPC title
Eye, e.g. artificial tears · CPC title
Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.